Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

13 Jul 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Background. With the widespread use of novel therapeutic agents, an increasing number of drugs have been confirmed to be associated with interstitial lung disease (ILD). However, real-world evidence regarding ILD reporting signals in patients with head and neck squamous cell carcinoma (HNSCC) remains limited.
Methods. We performed a signal mining study using data from the FDA Adverse Event Reporting System (FAERS) database from Q1 2004 to Q1 2025. Eligible adverse event reports related to ILD in HNSCC patients were included.
Disproportionality analysis was performed using the combination of reporting odds ratio (ROR) and information component (IC). Time to onset (TTO) was analyzed using descriptive statistics and Weibull distribution modeling. Results.
A total of 513 patients with ILD related to HNSCC treatment in the FAERS database were included. The median age was 68.00 years (IQR 60.00-75.00), the median weight was 56.00kg (IQR 47.80-68.00), and a total of 42 drugs were involved.

Clinical Editorial

Frontiers in Immunology published a clinical update in Infectious Disease on 13 Jul 2026.

The item focuses on Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

ClinicalTrialsRelated by Drugpembrolizumab

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Infectious Disease • 13 Apr 2026

NatureRelated by Drugnivolumab

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial

Research Highlights • 10 Jul 2026

medRxivRelated by Drugpembrolizumab

Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer

Research Highlights • 09 Jul 2026

Nat Rev OncRelated by Drugpembrolizumab

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Oncology • 17 Jun 2026

ClinicalTrialsRelated by Drugpembrolizumab

Surgical Pembro +/- Olaparib w TMZ for rGBM

Oncology • 04 Mar 2026

Feed Metadata

Source

Frontiers in Immunology

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

GIST (Key Takeaways)

Clinical Editorial

Source Reference

Related by Condition/Drug

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial

Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer

New standards and new&#xa0;constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

GIST (Key Takeaways)

Clinical Editorial

Source Reference

Related by Condition/Drug

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial

Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer

New standards and new&#xa0;constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer